Literature DB >> 22419364

Value of p16(INK4a) in the diagnosis of low-grade urothelial carcinoma of the urinary bladder in urinary cytology.

Francesc Alameda1, Nuria Juanpere, Lara Pijuan, Belen Lloveras, Javier Gimeno, Teresa Baró, Marta Salido, Sergio Serrano, Josep Lloreta.   

Abstract

BACKGROUND: The sensitivity of urinary cytology for the diagnosis of urothelial carcinomas is low, particularly in low-grade carcinomas. The UroVysion test is a fluorescent in situ hybridization multiprobe assay that increases the sensitivity of urinary cytology. However, this test is not widely available. P16(INK4a) , a protein involved in cell cycle progression, is overexpressed in urothelial carcinoma. Immunocytochemical expression of p16(INK4a) has been examined in biopsy samples from urothelial carcinomas, but few studies have addressed this protein in urine cytology.
METHODS: The authors compared the results of p16(INK4a) immunoreactivity in cytology and biopsy samples from 83 cases, including low-grade urothelial carcinomas, reactive epithelial lesions, and negative cases.
RESULTS: p16(INK4a) assessment of in urine cytology samples showed a sensitivity of 66.7% and a specificity of 82.8% in the diagnosis of low-grade urothelial carcinomas.
CONCLUSIONS: On the basis of these results, the authors propose that immunocytochemical detection of p16(INK4a) is a reliable tool in urine cytology, both for the diagnosis of low-grade urothelial carcinomas and for follow-up purposes. More retrospective and prospective studies are required to verify these results.
Copyright © 2012 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22419364     DOI: 10.1002/cncy.21193

Source DB:  PubMed          Journal:  Cancer Cytopathol        ISSN: 1934-662X            Impact factor:   5.284


  4 in total

Review 1.  [Urine cytology - update 2013. A systematic review of recent literature].

Authors:  M Böhm; F vom Dorp; M Schostak; O W Hakenberg
Journal:  Urologe A       Date:  2013-09       Impact factor: 0.639

2.  Expression of MDM2 mRNA, MDM2, P53 and P16 Proteins in Urothelial Lesions in the View of the WHO 4th Edition Guidelines as a Molecular Insight towards Personalized Medicine.

Authors:  Olfat Hammam; Mona Magdy; Mohamed Badawy; Khalid Al Osili; Amr El Kholy; Tarek El LeitHy
Journal:  Open Access Maced J Med Sci       Date:  2017-08-05

3.  Unbiased enrichment of urine exfoliated cells on nanostructured substrates for sensitive detection of urothelial tumor cells.

Authors:  Xin Wang; Yuanyuan Gu; Shiwei Zhang; Gangqiang Li; Tianyao Liu; Tianwei Wang; Haixiang Qin; Bo Jiang; Lin Zhu; Yajun Li; Haozhi Lei; Ming Li; Qun Zhang; Rong Yang; Feng Fang; Hongqian Guo
Journal:  Cancer Med       Date:  2019-11-10       Impact factor: 4.452

4.  Immunocytochemical expression of Ki-67/p16 in normal, atypical, and neoplastic cells in urine cytology using BD SurePath™ as preparation method.

Authors:  Kirsten Margrethe Østbye; Mette Kristin Pedersen; Torill Sauer
Journal:  Cytojournal       Date:  2019-12-05       Impact factor: 2.091

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.